ISCOM型白血病瘤苗联合1-甲基色氨酸免疫治疗荷瘤小鼠疗效观察  

The treatment effect of ISCOM leukemia vaccine combination with 1-methyl tryptophan on tumor burden mice

作　　者：黄琰[1] 吴隼[1] 字友梅[1] 张媛[1] 杨满[1] 马栋[1] 贺立山[1] 

机构地区：[1]新乡医学院第一附属医院血液科,河南新乡453100

出　　处：《重庆医学》2016年第1期37-39,共3页Chongqing medicine

基　　金：河南省教育厅基金资助项目(2006320039)

摘　　要：目的探讨免疫刺激复合物(ISCOM)型白血病肿瘤疫苗(简称瘤苗)联合1-甲基色氨酸对荷瘤小鼠的治疗作用。方法皂苷溶液中加入脂肪酶蛋白(1 mg/mL)7℃反应12h,加入80μL脂类混合物溶液和5 mL皂苷溶液(1 mg/mL)制备ISCOM型白血病瘤苗。C57BL/6小鼠分为模型组、ISCOM型白血病瘤苗组、1-甲基色氨酸组和联用组(ISCOM型白血病瘤苗+1-甲基色氨酸),小鼠注射FBL-3细胞建立白血病荷瘤小鼠模型,模型组给予等量生理盐水,其余各组接受对应药物治疗4周后,记录体质量,NK细胞、Mφ细胞和细胞毒T淋巴细胞(CTL)细胞杀伤活性、血清IL-10和IL-12表达水平。结果联用组瘤质量低于1-甲基色氨酸组和ISCOM型白血病瘤苗组[(0.64±0.26)g vs.(2.49±0.91)g,P<0.01;(0.64±0.26)g vs.(1.28±0.73)g,P<0.05)];联用组Mφ细胞杀伤活性显著高于1-甲基色氨酸组[(55.69±13.69)%vs.(69.47±14.79)%,P<0.01)];联用组NK细胞杀伤活性显著高于1-甲基色氨酸组[(38.41±8.27)%vs.(67.22±12.74)%,P<0.01];联用组CTL细胞杀伤活性高于1-甲基色氨酸组和ISCOM型白血病瘤苗组[(43.77±8.89)%vs.(69.68±11.44)%,P<0.01;(58.87±9.45)%vs.(69.68±11.44)%,P<0.05)];联用组IL-10均显著低于1-甲基色氨酸组、ISCOM型白血病瘤苗组[(76.2±6.82)pg/L vs.(98.3±13.4)pg/L,P<0.01;(76.2±6.82)pg/L vs.(202.3±44.5)pg/L,P<0.01)];联用组IL-12高于1-甲基色氨酸组、ISCOM型白血病瘤苗组[(381.2±47.3)pg/L vs.(332.1±30.2)pg/L,P<0.05;(381.2±47.3)pg/L vs.(291.2±17.3)pg/L,P<0.01)。结论 ISCOM白血病瘤苗联合1-甲基色氨酸具有较佳的抗瘤活性,其机制可能是通过介导IL-10和IL-12的表达。Objective Investigated the treatment effect of ISCOM leukemia vaccine combination with 1-methyl tryptophan on tumor burden mice. Methods Saponin was added lipase protein （1 mg/mL） 7 ℃for 12 h,adding 80 μL lipid mixed solution and 5 mL saponin solution （1 mg/mL） to prepare ISCOM leukemia vaccine. C57BL/6 mice were randomly divided into model group, ISCOM leukemia vaccine group, 1-methyl tryptophan group and combination group, Mice were injected FBL-3 cell to built leukemia tumor-burdened mice model. After treatment for 4 weeks, tumors weight,NK and Mφ and CTL cell killing activity, serum levels of IL-10,IL-12 were detected. Results Tumor weight in combination group was less than 1-methyl tryptophan and ISCOM leukemia group [（0.64±0.26）g vs. （2.49±0.91）g,P〈0.01 .（0.64±0.26）g vs. （1.28±0.73）g,P〈0.05];NK cell killing activity in combination group was higher than 1-methyl tryptophan group[（38.41±8. 27）% vs. （67.22± 12. 74）%, all P〈0.01）] ;Mφ activity in combination group was significantly higher than 1-methyl tryptophan group[（55.69±13.69） % vs. （69.47±14.79） %, P〈0.01] CTL activity in combination group was significantly higher than 1-methyl tryptophan group and ISCOM leukemia group[（43.77± 8.89）% vs. （69.68 ± 11.44） %, P〈0. 01, （58.87 ± 9.45） % vs. （69.68 ± 11.44）%, P〈0. 05];IL-10 in combination group were significantly lower than 1 - methyl tryptophan group and [SCOM leukemia group [（76.2 ± 6.82） pg/L vs. （98.3 ± 13.4） pg/L, P〈 0.01,（76.2±6.82）pg/L vs. （202.3±44.5） pg/L,P〈0.01] ;IL-12 in combination group were significantly higher than 1-methyl tryptophan group and ISCOM leukemia group[（38I. 2±47.3）pg/L vs, （332.1 ±30.2）pg/L, P〈0.05, （381.2 ± 47.3）pg/L vs. （291.2±17.3）pg/L,P〈0.01]. Conclusion Combination with 1-methyl tryptophan and ISCOM leukemia vaccine has a well antitumor effect.its mechanism may be through mediated and the expression of IL-12 and IL-10.

关 键 词：ISCOM型瘤苗 1-甲基色氨酸 前体细胞淋巴母细胞白血病/淋巴瘤 联用 

分 类 号：R733.7[医药卫生—肿瘤]